Stocks · News reference

Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027

Jul 30, 2026, 11:35 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 18, 2026, 9:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came
Read original at benzinga
AHG APUS CRIS HCWB IMCC
BenzingaAug 14, 2026, 2:36 PMBenzinga Newsdesk
Tvardi Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Read original at benzinga
TVRD
BenzingaAug 14, 2026, 11:07 AMBenzinga Newsdesk
Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of $(1.00) per share from
Read original at benzinga
TVRD
SEC EDGARAug 14, 2026, 11:05 AMSEC EDGAR
8-K filing — Tvardi Therapeutics, Inc. (TVRD)
Filed: 2026-08-14 AccNo: 0001104659-26-096417 Size: 276 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
TVRD